公开(公告)号：US20210040205A1

公开(公告)日：2021-02-11

申请号：US16758748

申请日：2018-10-23

Applicant: NOVARTIS AG

Inventor： Sunyoung JANG ,  Haihui LU ,  Matthew John MEYER ,  Ryan MOLONY ,  Karrie WONG

IPC: C07K16/28 ,  A61K47/68 ,  A61K45/06

Abstract: The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.

公开(公告)号：US20170198040A1

公开(公告)日：2017-07-13

申请号：US15382251

申请日：2016-12-16

Applicant: Novartis AG

Inventor： Nicole BALKE ,  Thomas CALZASCIA ,  Stefan EWERT ,  Alan HARRIS ,  Heather Adkins HUET ,  Isabelle ISNARDI ,  Haihui LU ,  Matthew John MEYER ,  Nicholas WILSON ,  Fangmin WU

IPC: C07K16/28 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/541 ,  A61K2039/545 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.

公开(公告)号：US20230295322A1

公开(公告)日：2023-09-21

申请号：US17934064

申请日：2022-09-21

Applicant: NOVARTIS AG

Inventor： Aida ABUJOUB ,  John BLANKENSHIP ,  Tony FLEMING ,  Brian HOLMBERG ,  Connie HONG ,  Lu HUANG ,  Haihui LU

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/46 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  A61K39/3955 ,  C07K16/2896 ,  C07K16/2866 ,  C07K16/283 ,  A61K2039/505

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US20240025993A1

公开(公告)日：2024-01-25

申请号：US18035470

申请日：2021-11-04

Applicant: NOVARTIS AG

Inventor： Regis CEBE ,  Dattananda CHELUR ,  Brian Walter GRANDA ,  Connie WONG ,  Sunyoung JANG ,  Haihui LU ,  Amy RAYO ,  Darko SKEGRO

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/55

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

公开(公告)号：US20220332821A1

公开(公告)日：2022-10-20

申请号：US17620987

申请日：2020-06-22

Applicant: NOVARTIS AG

Inventor： Kimberly AARDALEN ,  Aida ABUJOUB ,  John BLANKENSHIP ,  Anuradha CONNOR ,  Mirek DOSTALEK ,  Tony FLEMING ,  Brian HOLMBERG ,  Connie HONG ,  Lu HUANG ,  Haihui LU ,  K. Gary J. VANASSE

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/167 ,  A61K31/417 ,  A61K31/56

Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.